Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291102 · ClinicalTrials.gov registry record · Phase 3
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
A Phase 3 study, sponsored by Nationwide Children's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT07291102: Clinical Trial Phase 3 study, sponsored by Nationwide Children's Hospital.
NCT07291102 is a Phase 3 study that has not yet begun recruiting, run by Nationwide Children's Hospital. The registered enrollment target is 96 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07291102, a Phase 3 study, has not yet begun recruiting, sponsored by Nationwide Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
Primary Outcome
To compare neurocognitive outcomes 2.5 years after diagnosis between patients randomized to the interventional arms A ("Head Start" 4) and B (HIT-SKK). Full-Scale Intelligence Quotient (IQ) as measured by the Wechsler Preschool and Primary Scale of Intelligence (WPPSIIV) administered to those between the ages of 2 years and 6 months to 7 years and 7 months old at 2.5 years after diagnosis (+/- 6 months).
Interventions
- DRUG Bridging Chemotherapy
- DRUG Induction Cycles A1-A3
- DRUG Induction Cycles A4-5
- DRUG Consolidation Cycle A6
- DRUG HIT-SKK Chemotherapy Cycles B1-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2038-10 |
| Phase | Phase 3 |
What is known before NCT07291102 opens enrollment
NCT07291102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which Bridging Chemotherapy is the first listed.
NCT07291102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07291102 about?
NCT07291102 is a clinical study titled "Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma". This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
What is the current status of trial NCT07291102?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2026-07-01. Estimated completion is 2038-10.
What interventions are being tested in trial NCT07291102?
The interventions under investigation include: Bridging Chemotherapy (DRUG), Induction Cycles A1-A3 (DRUG), Induction Cycles A4-5 (DRUG), Consolidation Cycle A6 (DRUG), HIT-SKK Chemotherapy Cycles B1-3 (DRUG).
Who is sponsoring clinical trial NCT07291102?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07291102's enrollment target sits among peer trials
96 1718th of 2000 higher than 282 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI